A378800 Stock Overview
A clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shaperon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,500.00 |
| 52 Week High | ₩5,900.00 |
| 52 Week Low | ₩1,389.00 |
| Beta | -0.040 |
| 1 Month Change | -3.18% |
| 3 Month Change | -10.83% |
| 1 Year Change | -6.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.44% |
Recent News & Updates
Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?
Dec 20
We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn Rate
Sep 02Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?
Apr 12Shareholder Returns
| A378800 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.4% | 3.0% | -1.5% |
| 1Y | -6.9% | 12.2% | -12.2% |
Return vs Industry: A378800 underperformed the KR Biotechs industry which returned 8.4% over the past year.
Return vs Market: A378800 exceeded the KR Market which returned -12.2% over the past year.
Price Volatility
| A378800 volatility | |
|---|---|
| A378800 Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A378800's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A378800's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 50 | Seung-Yong Seong | www.shaperon.com |
Shaperon Inc., a clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics. It offers NuGel, a gel type atopic dermatitis drug candidate in Phase 2 clinical trials; and NuSepin, an IV injection form of HY209 in Phase 2 clinical trials for use in the treatment of systemic inflammatory response syndrome. The company also provides Oral HY209, an oral formulation of HY209 for use in the treatment of neuroinflammatory diseases; and HY209 Analogues for treating chronic inflammation.
Shaperon Inc. Fundamentals Summary
| A378800 fundamental statistics | |
|---|---|
| Market cap | ₩105.50b |
| Earnings (TTM) | -₩15.90b |
| Revenue (TTM) | ₩91.24m |
1,156x
P/S Ratio-6.6x
P/E RatioIs A378800 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A378800 income statement (TTM) | |
|---|---|
| Revenue | ₩91.24m |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩91.24m |
| Other Expenses | ₩16.00b |
| Earnings | -₩15.90b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -527.65 |
| Gross Margin | 100.00% |
| Net Profit Margin | -17,432.45% |
| Debt/Equity Ratio | 0% |
How did A378800 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 07:45 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shaperon Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|